Videos

Keytruda Side Effects: ‘If Something Doesn’t Feel Right … Call’

January 26th 2024, 11:00pm

Video

Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said.

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

January 24th 2024, 10:00pm

Video

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.

What Patients With Liver Cancer Need to Know About Hepatitis B and C

January 24th 2024, 2:00pm

Video

“In my career of almost 30 years, I've never seen a liver cancer patient that did not have a chronic underlying liver disease,” Dr. Mindie H. Nguyen told CURE®.

Step Count Gives Insight to GI Cancer Outcomes in Older Patients

January 23rd 2024, 11:00pm

Video

Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.

3-Drug Regimen May Be Underutilized in Metastatic CRC

January 20th 2024, 8:00pm

Video

The use of FOLFOXIRI for metastatic colorectal cancer was lower than one what expert was expecting.

Key Takeaways for Patients With Myelofibrosis

January 19th 2024, 1:00pm

Video

Patients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.

Differentiating Muscle-Invasive, Non-Muscle-Invasive Bladder Cancer

January 12th 2024, 8:00pm

Video

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer.

Dosing JAK Inhibitors in Patients With Myelofibrosis

January 12th 2024, 1:30pm

Video

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Best Approaches to Switching Therapies for a Patient With Myelofibrosis

January 12th 2024, 1:00pm

Video

Reasons to switch JAK inhibitors include worsening blood counts and insufficient symptom or spleen response at maximum doses, with the goal of avoiding gaps in treatment by stopping one JAK inhibitor when ready to start the next to prevent symptom rebound while still allowing for potential increased efficacy from an alternative mechanism of action.

More Is Needed to Connect Clinicians, Patients to Clinical Trials

January 9th 2024, 2:00pm

Video

More facilitation is needed to ensure that clinicians can connect patients with breast cancer to clinical trials they may be eligible for.